-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Initiates Coverage On Lycia Therapeutics with Buy Rating, Announces Price Target of $50

Benzinga·11/17/2026 13:01:03
Jefferies analyst Faisal Khurshid initiates coverage on Lycia Therapeutics (NASDAQ:LYCA) with a Buy rating and announces Price Target of $50.